Company Overview
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity that discovers, develops, licenses, manufactures, markets, distributes, and sells specialized medical products. The organization functions within the Healthcare sector, specifically categorized under the Drug Manufacturers - General industry, which signifies its role in providing essential therapeutic solutions to patients worldwide. The company demonstrates significant scale with a market capitalization of $119.52B and an annual revenue of $48.19B, supported by a workforce of 32,500 employees. These valuation and revenue figures indicate that Bristol-Myers Squibb holds a substantial position in the pharmaceutical landscape, reflecting its extensive reach in oncology, hematology, immunology, cardiovascular, and neuroscience fields.
Financial Health
The company reported a revenue of $48.19B, net income of $7.05B, and EBITDA of $19.12B for the trailing twelve months. The substantial gap between the $48.19B revenue and the $7.05B net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately $41.14B of gross proceeds before reaching the bottom line. The company generated free cash flow of $11.15B, which provides a robust foundation for financial flexibility to fund research, development, and strategic acquisitions without relying heavily on external financing. Profitability is analyzed through three key margins: a gross margin of 72.6% indicates high pricing power and efficient production relative to sales, an operating margin of 28.2% reflects strong operational efficiency after covering direct and indirect costs, and a profit margin of 14.6% demonstrates the final profitability retained for shareholders. Regarding leverage, the company holds $10.67B in cash against $47.19B in debt, resulting in a debt-to-equity ratio of 254.98, which suggests a highly leveraged balance sheet typical for capital-intensive pharmaceutical firms. Short-term liquidity is assessed via a current ratio of 1.25, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a margin of safety. Management effectiveness is highlighted by a return on equity of 40.4% and a return on assets of 10.3%, metrics that reveal highly efficient capital deployment and significant value generation relative to the equity invested and total assets utilized.
Valuation Assessment
The stock trades with a trailing P/E ratio of 16.92 and a forward P/E of 9.53, implying that the market expects earnings to grow significantly to meet the lower forward multiple. The price-to-book ratio stands at 6.45, indicating that the market values the company at a substantial premium over its net asset book value, likely due to intangible assets like intellectual property and brand strength. Alternative valuation metrics include a price-to-sales ratio of 2.48 and an EV/EBITDA of 8.15, which suggest the company is valued reasonably relative to its sales volume and enterprise earnings before interest, taxes, depreciation, and amortization. The 52-week trading range spans from a low of $42.52 to a high of $62.89, providing context for current price positioning relative to historical volatility over the past year. The stock exhibits a beta of 0.27, indicating that its price volatility is significantly lower than that of the broader market, making it less sensitive to general equity market fluctuations.
Growth & Income
Revenue growth for the year stands at 1.3%, while earnings growth for the year is recorded at 1392.1%, showing that earnings are expanding at a vastly faster rate than revenue due to a sharp increase in the net income figure. As a dividend payer, the company offers a dividend yield of 4.3% with a payout ratio of 72.0%, suggesting that the payout ratio is high but supported by the reported net income levels. The high earnings growth rate relative to revenue growth implies that the company is optimizing its cost structure or realizing significant one-time gains, though the revenue growth remains modest. The overall growth and income profile presents a blend of moderate top-line expansion, exceptional bottom-line performance, and a substantial return of capital to shareholders through dividends.